RecruitingNCT06559761

Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research


Sponsor

Chinese PLA General Hospital

Enrollment

500 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Hepatocellular carcinoma (HCC) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. Currently, there is a lack of non-invasive and simple indicators to predict the prognosis of HCC patients and assist clinical decision-making. The identification of HCC macroscopic or histopathological classification requires large pathological specimens obtained through surgical resection, but only about 20% of patients are eligible for surgical treatment. Moreover, most liver cancer diagnoses can be confirmed by imaging examinations without relying on pathological results. For patients who have not undergone surgical resection, the lack of histopathological information during treatment means that there is no basis for judging tumor proliferation and obtaining rich prognostic information. Therefore, evaluating the invasion and proliferation ability of HCC based on macroscopic imaging assessment has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. Ultrasound and MRI are ideal entry points as first-line imaging methods for liver cancer diagnosis. This study aims to evaluate HCC macroscopic or histopathological classification based on multimodal imaging (ultrasound, CT, MRI), thereby assessing its invasion and proliferation ability which has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. By analyzing macroscopic image features we aim to explore their cross-scale correlations with HCC macroscopic classification,histopathological classification,and gene molecular typing.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study examines whether features visible on routine medical imaging scans (CT or MRI) can accurately predict how aggressively a patient's liver cancer (hepatocellular carcinoma) will behave after surgical removal — for example, how likely it is to recur or spread. The goal is to help doctors identify high-risk patients earlier, without needing additional invasive tests. **You may be eligible if...** - You are aged 18–80 with a confirmed diagnosis of liver cancer (hepatocellular carcinoma) - Your treatment plan involves surgery with curative intent - There is no evidence of major blood vessel invasion, spread to lymph nodes, or spread to other organs at the time of surgery **You may NOT be eligible if...** - You do not meet all of the inclusion criteria above - You are unwilling or unable to attend regular follow-up appointments after surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHepatectomy

According to guideline recommended procedure of hepatectomy


Locations(1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06559761